Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - ADIAL PHARMACEUTICALS, INC. | f10k2019_adialpharma.htm |
| EX-32.1 - CERTIFICATION - ADIAL PHARMACEUTICALS, INC. | f10k2019ex32-1_adial.htm |
| EX-31.2 - CERTIFICATION - ADIAL PHARMACEUTICALS, INC. | f10k2019ex31-2_adial.htm |
| EX-31.1 - CERTIFICATION - ADIAL PHARMACEUTICALS, INC. | f10k2019ex31-1_adial.htm |
| EX-23.1 - CONSENT OF FRIEDMAN LLP - ADIAL PHARMACEUTICALS, INC. | f10k2019ex23-1_adial.htm |
| EX-21.1 - LIST OF SUBSIDIARIES OF ADIAL PHARMACEUTICALS, INC. - ADIAL PHARMACEUTICALS, INC. | f10k2019ex21-1_adial.htm |
| EX-4.33 - DESCRIPTION OF SECURITIES - ADIAL PHARMACEUTICALS, INC. | f10k2019ex4-33_adial.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Adial Pharmaceuticals, Inc. (the “Registrant”) on Form 10-K for the period ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Truluck, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
| Date: March 20, 2020 | By: | /s/ Joseph Truluck |
| Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) |